SUBSCRIBERS
Big pharma turns to artificial intelligence to speed up drug discovery process
Published Sun, Jul 2, 2017 · 09:50 PM
London
THE world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with Glaxo-SmithKline unveiling a new US$43 million deal in the field on Sunday.
Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Technology
Brokers’ take: DBS cuts Venture Corp price target after Q1 earnings miss
Garmin’s Q1 results beat on strong demand for fitness, auto products
Foxconn’s musical chairs sound like punk rock
US sets up board to advise on safe, secure use of AI
Regulate AI? How US, EU and China are going about It
Meta’s results are best viewed through rose-tinted AI glasses